Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review

Saeed Shoar1, Adriana C. Carolina Prada-Ruiz2, Gabriel Patarroyo-Aponte3, Ashok Chaudhary4 and Mohammad Sadegh Asadi5

1Department of Clinical Research, Scientific Collaborative Initiative, Houston, TX, USA. 2Division of Pediatric Cardiology, Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, TX, USA. 3Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. 4Department of Internal Medicine, Griffin Hospital, Derby, CT, USA. 5Division of Cardiology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

ABSTRACT

BACKGROUND: Heart transplant (HTX) recipients are at a significantly higher risk of adverse clinical outcomes, due to chronic immunosuppression and co-existence of other chronic conditions, when contracting the SARS-CoV-2 infection. Although vaccination against SARS-CoV-2 is currently the most promising measure for the prevention of severe Coronavirus Disease 2019 (COVID-19) among solid organ transplant recipients, the extent of immune response and its protective efficacy among patients receiving HTX has not been sufficiently studied.

METHODS: We performed a systematic review of the literature by inquiring PubMed/Medline to identify original studies among HTX recipients, who had received at least one dose of the SARS-CoV-2 vaccine. Data on the measured humoral or cellular immune response was collected from all the eligible studies. Factors associated with a poor immune response were further investigated within these studies.

RESULTS: A total of 12 studies comprising 563 HTX recipients were included. The average age of the study participants was 60.8 years. Sixty-four percent of the study population were male. Ninety percent of the patients had received an mRNA vaccine (Pfizer/BNT162b2 or Moderna/mRNA-1273). A positive immune response to SARS-CoV-2 vaccine was variably reported in 0% to 100% of the patients. Older age (> 65 years), vaccine dose (first, second, or third), time since HTX to the first dose of the vaccine, the time interval between the latest dose of the vaccine and measurement of the immune response, and the type of immunosuppressive regimen were all indicated as potential determinants of a robust immune response to the SARS-CoV-2 vaccination.

CONCLUSION: HTX recipients demonstrate a weaker immune response to the vaccination against SARS-CoV-2 compared to the general population. Older age, anti-metabolite agents such as mycophenolate mofetil, and vaccination during the first year following the HTX have been indicated as potential determinants of a poor immune response.

KEYWORDS: SARS-CoV-2 vaccine, COVID-19, heart transplant, cardiac transplantation, immunization, humoral immune response, cellular immune response

Introduction

At the time of writing this article, 79,555,007 cases of coronavirus diseases 2019 (COVID-19) have been identified in the U.S. with a total of 968,839 reported deaths.1 Additionally, 254,984,673 individuals have received at least one dose of a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite declining trend in the number of new cases of COVID-19 and hospitalization rate, the number of patients with pre-existing comorbidities, who are at the risk of developing severe COVID-19 remains high.2

In patients with COVID-19, the severity of the disease, worse clinical outcome, and mortality are correlated with the intensity of the hyper-inflammatory response in the form of a cytokine storm.3-5 Additionally, those with pre-existing comorbidities are at an additional risk for development of poor clinical outcome and mortality.6

Heart transplant (HTX) recipients constitute a high-risk population of patients in the setting of COVID-19.7-9 In addition to harboring higher number of comorbidities,10 HTX patients have a suppressed immune state, which has been a controversial risk factor for the development of more severe COVID-19 or poor clinical outcomes.7,8,11 At present, vaccination against COVID-19 is the only preventive measure to mitigate the severity of the diseases, reduce hospitalization rate and mortality, and ultimately end the pandemic.12-14 However, due to chronic immunosuppression and existence of multiple comorbidities, production of sufficient anti-SARS-CoV-2 spike immunoglobulin titer or effective neutralizing antibody after vaccination against COVID-19 has been variable among patients with a transplanted solid organ.15-21

As HTX patients constitute a unique population of transplant recipients, we aimed to conduct this systematic review...
to summarize scarce data in the literature on the development of immune response following vaccination against SARS-CoV-2 and factors associated with a weaker immunity.

**Methods & Materials**

**Study design**

A systematic review was conducted according to the Reporting Guidelines for Meta-analyses of Observational Studies (MOOSE). Two reviewers (SS and GP) independently searched the literature to identify articles addressing SARS-CoV-2 vaccination in patients with HTX. Any conflict was resolved by discussing with the third investigator (MSA). The protocol for this systematic review has been registered with the Open Science Framework and is available to the public (DOI:10.17605/OSF.IO/HV4FJ).

**Literature review**

The literature review was performed by electronic query of the online database Medline/PubMed using the following combination of search terms: (COVID-19 vaccin* OR SARS-CoV-2 vaccin*) AND (Cardiac transplant* OR Heart transplant*). The title and abstract of the retrieved articles were reviewed for relevancy. The full text of relevant articles was further assessed for eligibility. The reference list of eligible studies and relevant review articles were also manually reviewed for additional citations.

**Study selection**

Studies were eligible if they were in English language, reported on human subjects older than 18 years, and measured the immune response to SARS-CoV-2 vaccination in HTX recipients. Studies were not eligible if they were animal experiments, editorial/commentary, or review articles. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) throughout the literature review and for study selection (Figure 1).

**Data collection**

Data pertinent to the variables of interest was collected from eligible studies. This included age, gender, country of origin, features of COVID-19 vaccine such as type, dose, and time from the latest dose of vaccine to the time of measuring the immune response, time interval from HTX to the first dose of vaccine, immunosuppressive regimen, and the study conclusion on vaccine efficacy.

**Outcome measure**

The primary endpoint of this systematic review was to determine a detectable response rate to SARS-CoV-2 vaccine in HTX recipients. The secondary endpoint of this study was to elaborate on factors associated with a poor immune response.

**Statistical analysis**

Extracted data from eligible studies were examined by simple descriptive statistics and in a qualitative manner. Continuous variables are presented as mean ± standard deviation (±SD) or median [interquartile range]. Categorical variables are presented as percentages. Due to a small number of HTX cases and a large heterogeneity in the measurement and reporting of the data, a more vigorous statistical analysis was not feasible and hence not performed.

**Results**

A total of 61 records were identified through December 2021 by electronic inquiry of PubMed/Medline and manual search of the bibliography list of relevant review articles. The full text of 18 studies was further evaluated for eligibility. Of these, 12 articles were eligible to be included into this systematic review (Figure 1). This encompassed a total of 563 HTX recipients with an average age of 60.8 years (range: 18-80), who received at least 1 dose of SARS-CoV-2 vaccine. Out of the studies with a reported gender distribution (496 patients), 319 were male (64.3%) and 177 were female (35.7%). The patient population enrolled in these studies were from Israel, Europe (Italy, Spain, Germany, and Greece), Taiwan, and the USA (Table 1).

The utilized vaccines for the immunization of HTX recipients against SARS-CoV-2 were Pfizer/BNT162b2 (449 patients, 79.7%), Moderna/mRNA-1273 (122 patients, 19.9%), Johnson & Johnson/Ad26.COV2.S (1 patient, 0.2%), and AstraZeneca/AZD1222 (ChAdOx1 nCoV-19) (1 patient, 0.2%). Immune response was measured after the second dose of an mRNA vaccine in 464 patients (82.4%), after the third dose of an mRNA vaccine in 96 patients (17.05%), after the first dose of an mRNA vaccine in 1 patient (0.17%), and after the single dose of the vector-based vaccine in 2 patients (0.35%).

Time to administration of the first dose of COVID-19 vaccination ranged from 8 days before to more than 166 months after HTX (Table 2). Time from the last dose of the vaccine (first, second, or third) to the time of the last measurement of the immune response ranged from 9 days to 10 weeks. Studies included in this systematic review utilized a combination of humoral and/or cellular immunoassay in measuring the immune response against SARS-CoV-2 vaccine among HTX recipients. This included anti-receptor binding domain (RBD), anti-spike, or anti-nucleocapsid antibody levels (measured as a titer or as a positive response rate), neutralization or pseudo-neutralization activity of anti-SARS-CoV-2 antibodies, interferon-γ assay, and peripheral T-cell counts or its subsets (CD4+ and CD3+ cells).
Regardless of the laboratory test, immune response (humoral or cellular), or the manufacturer-provided cut-off for the detection of an immune response, a positive response was variably observed in 0% to 100% of the HTX recipients. Based on a qualitative appraisal of the included studies, a weaker immune response was implicated in relation to an age > 65 years,\textsuperscript{24,28} male gender, a short time interval between the second dose of the SARS-CoV-2 vaccine and the time of measuring the immune response,\textsuperscript{28} vaccination within the first year after HTX, antimetabolite immunosuppressant,\textsuperscript{19,21,24,27} and a weaker cellular immune response.\textsuperscript{25,29}

**Discussion**

Our systematic review and qualitative analysis of the literature on the immune response to SARS-CoV-2 vaccination observed a weaken humoral immune response among HTX recipients. Although more studies are required, older age, antimetabolite immunosuppressants, and vaccination within the first year of HTX seemed to be associated with a weak immune response to SARS-CoV-2 vaccine. Yet, no study has demonstrated an association between race, or socioeconomic status, and the strength of the immune response.

In a prospective cohort of 658 solid organ recipients, Boyarsky et al. measured the humoral response against RBD of the SARS-CoV-2 spike protein after the first and second dose of the vaccine.\textsuperscript{16} At a median (IQR) of 21 (18-25) days after the first dose, 15% of the patients developed a positive response while the positive response rate was 54% at a median (IQR) of 29 (28-31) days after the second dose. On the opposite, 46% of the patients did not develop any antibody response after SARS-CoV-2 vaccine dose 1 or 2. Out of those receiving antimetabolite immunosuppressants, 8% developed a humoral response.
response to the first or the second dose compared to a 32% response rate in those receiving an immunosuppressant regimen besides antimetabolites. Although sex and race did not demonstrate any significant association with the response rate after either dose of the vaccine in this study, older age and shorter time interval since HTX were all associated with a higher probability of a weaker response to the SARS-CoV-2 vaccine. Interestingly, an enhanced response rate for humoral immunity after the second dose was noted among the middle-aged group (40-59 years), and in those who were 7 years and longer beyond HTX.

Erbel-Khurtsidze et al. presented a case with a robust immune response to one dose of SARS-CoV-2 vaccine, 3 months after contracting the SARS-CoV-2 infection and 8 days prior to receiving the HTX. However, it is noteworthy that both events, infection and vaccination, occurred prior to the HTX and initiation of the induction immunosuppression. In a cohort of 96 HTX recipients receiving 3 doses of SARS-CoV-2 vaccine, Peled et al. demonstrated a significantly higher rate of humoral and cellular immune response to SARS-CoV-2 vaccine after the third dose. Still, there was no humoral response in 33% of the HTX recipients. Younger age, stronger renal function, use of mycophenolate as the antimetabolite immunosuppression, and lower serum levels of C-reactive protein were significant predictors of a positive antibody response. Interestingly, a positive T-cell response was

| Table 1. Characteristics of studies included in our systematic review. |
|---------------------------------------------------------------|
| AUTHOR/YEAR       | COUNTRY | STUDY TYPE | SAMPLE SIZE | AGE (YEARS) | M:F       | VACCINE TYPE/ NUMBER OF DOSES | ANTIBODY RESPONSE MEASUREMENT |
|-------------------|---------|------------|-------------|-------------|-----------|-------------------------------|------------------------------|
| Rahav/2021        | Israel  | Prospective cohort | 80         | 61.5 [50-68] | 55:25     | BNT162b2/2                   | RBD IgG; pseudo-virus neutralization assay |
| Erbel-Khurtsidze/ 2021 | Germany | Case report | 1           | 61          | 1:0       | BNT162b2/1                   | Vaccine was given 8 days before HTX; anti spike and nucleocapsid Ig A/M/G and SARS-CoV-2 neutralization test were measured after dose of the vaccine and after HTX. |
| Itzhaki Ben Zadok/ 2021 | Israel  | Prospective cohort | 42         | 61 [44-69]  | 35:7      | BNT162b2/2                   | Anti-spike IgG                |
| Hallett/2021      | US      | Prospective cohort | 134        | 60 [44-60]  | 67:67     | BNT162b2/2 in 70 patients mRNA-1273 in 64 patients | Anti-spike IgG and RBD IgG |
| Loconsole/2021    | Italy   | Case report  | 1           | 65          | 1:0       | BNT162b2/2                   | Anti RBD IgG                  |
| Marinaki/2021     | Greece  | Case control | 24          | N/A         | N/A       | BNT162b2/2                   | RBD IgG                       |
| Peled (1)/2021    | Israel  | Prospective cohort | 77         | 62 [49-68]  | 50:27     | BNT162b2/2/3                 | Third dose was given 168 days after the second dose; RBD IgG and neutralizing antibodies were measured. |
| Peled (2)/2021    | Israel  | Prospective cohort | 96         | 61.0 [49.8-68.0]  | 68:28     | BNT162b2/3                   | Third dose was given 168 days after the second dose; RBD IgG and neutralizing antibodies were measured. |
| Herrera/2021      | Spain   | Prospective cohort | 46         | 60 [20-80]  | 33:13     | mRNA-1273/2                  | Both humoral (IgM and IgG) antibodies (RBD) and cellular immunity (interferon-γ) were measured. |
| Tang/2021         | Taiwan  | Case report  | 1           | 51          | 1:0       | ChAdOx1 nCoV-19 vaccine (AstraZeneca)/1 | Epstein-Barr virus (EBV) induced diffuse large B-cell lymphoma, which occurred 7 days after the first dose of the vaccine; |
| Lemieux/2021      | US      | Case control | 18          | 59 years median | 8:10     | BNT162b2 in 15 patients mRNA-1273 in 2 patients Ad26.COV2.S in 1 patient | Cellular immune response, anti-RBD IgG, and pseudovirus neutralization activity were measured prior to and after the first and second doses of vaccination. |
| Schramm/2021      | Germany | Case control | 43          | 18 to >60   | N/A       | BNT162b2/2                   | Anti-SARS-CoV-2 IgG and neutralizing antibodies (B cell response) and interferon-γ (T cell response) were measured. |

M:F: Male to female ratio; HTX: Heart transplantation; RBD: Receptor binding domain; N/A: Not applicable; [] refers to 95% confidence interval;
| AUTHOR/YEAR        | TIME FROM HTX TO FIRST DOSE OF VACCINE | IMMUNOSUPPRESSIVE REGIMEN                                                                 | TIME FROM LAST DOSE OF VACCINE TO THE LATEST SEROLOGY MEASUREMENT (DAYS) | POSITIVE RESPONSE RATE* | ANTI SARS-COV-2 AB NA | CONCLUSION                                                                                                                                 |
|-------------------|----------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------|----------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Rahav/2021        | N/A                                    | N/A                                                                                       | 15/80 (18.8%)                                                            | RBD IgG antibody: 0.55 (0.44-0.68) | 53.8 GMT (24.1-120.4) | Antibody response was highly variable among different groups of patients on immunosuppression. Significant correlation existed between RBD IgG and NA. Female gender, age < 65 years, and time interval from the second dose of vaccine were associated with a stronger response. |
| Erbel-Khurtsidze/2021 | 8 days before Tacrolimus, corticosteroids, and mycophenolate | 37 days                                                                                   | 1/1 (100%)                                                               | >384 BAU/mL anti spike antibodies; >38.2 U/mL SARS-CoV-2-IgG/A/ M antibodies | 1:2560 | One dose of vaccine 3 months after COVID-19 infection and 8 days before HTX resulted in adequate anti-spike and anti-nucleocapsid antibody response after HTX. |
| Itzhaki Ben Zadok/2021 | 110 months (32-166) CNIs, mTORi, steroids, anti-metabolites | days 21-26 or days 35-40 after the first dose of the vaccine                              | 18/37 (49%)                                                             | GMT for anti-spike IgG: 426 AU/mL [106- 884] | Not measured | Older HTX recipients and those on antimitabolite immunosuppression were more likely to have low immunogenicity. |
| Hallett/2021      | 5.5 years (2.6-12.4) Tacrolimus, sirolimus, mycophenolate, corticosteroids, cyclosporine, azathioprine, everolimus, belatacept | 21 days [IQR, 19-26] after dose 1; 29 days [IQR, 28-32 days] after dose 2                  | 19/135 (14%) priming; 64/133 (48%) boosting                             | N/A                      | Not measured | Diminished antibody response was observed among HTX patients; antibody response after the prime dosage was associated with younger age, HTX-to-vaccination time ≥ 6 years, and no anti-metabolite as part of maintenance immunosuppression |
| Loononse/2021     | 7 years Anti-proliferative (mycophenolate mofetil) was halted and calcineurin inhibitor (cyclosporine) was reduced | 42 days after the second dose                                                             | 0/1; patient got COVID-19 despite vaccination                            | Anti-SARS-CoV-2 IgG: 23.01 AU/mL | Not measured | Immune response was sub-optimal in this HTX patient. |
| Marinaki/2021     | 11.1 [IQR: 7.3 -15.8] Calcineurin inhibitor-based immunosuppressive regimen, an anti-metabolite, corticosteroids, and an mTOR inhibitor | 10 days [9-10]                                                                           | 18/24 (75%)                                                             | Median Ab titer: 1370 U/mL; GMT of 948 U/mL | Not measured | Humoral antibody response was reduced compared to healthy counterparts. Antimetabolite immunosuppression was the only agent negatively influencing the immune response. |
| Peled (1)/2021     | 7.4 years [3.3-15.1] Mycophenolate, everolimus, cyclosporine, prednisone | 20.6 days ± 10.0                                                                         | 14 (18%)                                                                | N/A                      | 8 of 14 responders (57%) | Mycophenolic acid was associated with lower odds of an antibody; it remains unknown if a longer (continued)
| AUTHOR/YEAR | TIME FROM HTX TO FIRST DOSE OF VACCINE | IMMUNOSUPPRESSIVE REGIMEN | TIME FROM LAST DOSE OF VACCINE TO THE LATEST SEROLOGY MEASUREMENT (DAYS) | POSITIVE RESPONSE RATE* | ANTI SARS-COV-2 AB NA | CONCLUSION |
|------------|--------------------------------------|----------------------------|-----------------------------------------------------------------|------------------------|-----------------------|------------|
| Peled (2)/2021 | 5.9 years [2.9-13.1] | Mycophenolate, everolimus, cyclosporine, prednisonone | 17.5 days ± 3.9 | 64 (67%) | 1.58 GMT (95% CI 1.24 to 2.00) | 27.25 GMT (95% CI: 15.70 to 47.30) | The third/booster dose of BNT162b2 vaccine increased the neutralization titers 9 folds and IgG anti-RBD antibodies 3 folds after the second dose; it elicited the humoral and cellular immune responses consistently. |
| Herrera/2021 | 6.3 years (0.4-21) | Mycophenolate, calcineurin inhibitors, prednisone, mTOR inhibitors | 4 weeks | 40 (87%) | 2.44 [9.81] | N/A | Hypogammaglobulinemia, high dose of mycophenolic acid, and vaccination during the first year after transplantation were associated with vaccine unresponsiveness. |
| Tang/2021 | 6 years | Tacrolimus (1 mg twice a day) and mycophenolate mofetil | N/A | N/A | N/A | N/A | Vaccine might reactivate a latent EBV leading to B lymphocyte tumorigenesis. |
| Lemieux/2021 | 1 to > 15 years | DNA synthesis inhibitor, calcineurin inhibitor, prednisone, mTOR inhibitor | 8-10 weeks | N/A | N/A | N/A | Thirty days after the second vaccine dose, anti-RBD Ab and neutralizing Ab was 20 folds and 12 folds lower than healthy counter parts, respectively. The number of CD8+ T cells and CD19 + B cell populations was similar between HTX and normal controls. Higher number of peripheral T helpers and CD4+ T cell numbers were strongly associated with strong immune response. |
| Schramm/2021 | < 1 to > 3 years | Tacrolimus, cyclosporin, mTOR-inhibitor, mycophenolate mofetil | 21 days | 100% | 1417 BAU/mL [732-2589] | 0 after the first and 4% after the second dose (one patient) | Overall, anti-SARS CoV-2 IgG was significantly lower among HTX patients compared to healthy controls as was the interferon-γ response to spike antigens SARSCoV-2 peptides. |

HTX: Heart transplantation; Ab: Antibody; GMT: Geometric mean titer; RBD: Receptor binding domain; NA: Neutralization assay; BAU: Binding antibody unit; AU: Antibody unit; mTOR: mammalian target of rapamycin; N/A: Not available.

*Unless specified otherwise, antibody responses are after the second dose of COVID-19 vaccination.
observed in the majority of HTX recipients following the third dose of SARS-CoV-2 vaccine in the absence of a positive humoral/antibody response, suggesting a positive cellular immunity despite no antibody response. In another prospective study of 50 cardiothoracic transplant recipients, Schramm and colleagues measured the immune response to a full-dose BNT162b2 vaccine 10 to 36 months after HTX and compared it to healthy individuals. In contrast to 98% response rate in healthy individuals after the first dose, only 10% of the HTX recipients had a positive humoral or cellular immune response three weeks after the two-dose series of the vaccine. Such a poor immune response might be explained, in part, by shorter time interval after transplantation as all the patients were in their second to third year post-HTX. Although there was no significant difference between responders and non-responders to the third dose of SARS-CoV-2 vaccine in terms of the time after HTX in the study of Peled et al., such a time interval was significantly shorter among solid organ recipients in the study of Boyarsky et al. Besides an additional boosters given to the transplant patients in the former study, all were HTX recipients, compared to the latter in which a combination of heart, lung, kidney, liver, and pancreas had been transplanted.

The variation in the response rate to SARS-CoV-2 vaccine among HTX recipients can be, in part, explained by the different time interval from the latest dose of the vaccine to the time of serological testing. In a serological assay of 34 healthcare workers, who had received two doses of Pfizer/BNT162b2 in three weeks interval, Mueller et al. demonstrated that while anti-nucleocapsid antibody titer remained undetectable over a 5-week observation period, the anti-spike antibody constantly rose up 4 to 5 weeks after the first dose of the vaccine. A similar pattern of rapid increase in anti-SARS-CoV-2 antibody levels has been observed in the plasma obtained from US veterinarians, who had been vaccinated against SARS-CoV-2 between February 1st and September 30th, 2021 revealed that immunization with Moderna and Pfizer-BioNTech vaccines stays effective, 120 days after the second dose, in the prevention of hospitalization due to COVID-19, in 86% and 75% of the cases, respectively. This study included an older population of patients with multiple underlying comorbidities. Other studies have also indicated that an age > 65 years old and existence of comorbidities such as diabetes, chronic renal diseases, autoimmune and/or rheumatologic conditions, and malignancy are associated with a weaker immune response, an observation that is forming the evidence for current recommendation for booster doses. As these conditions are more prevalent among HTX recipients, the waning immunity in these patients after a series of vaccination against COVID-19 remains to be investigated by longitudinal studies. Of note, while humoral response is an important measure of immunity in the short run, cellular immunity plays a more important role when assessing the long-lasting protection against SARS-CoV-2.

Currently, several SARS-CoV-2 antibody tests manufactured by different research and commercial laboratories have received an emergency use authorization (EUA) from the United States Food and Drug Administration (FDA). Besides different techniques employed by these serological tests (Enzyme-linked immunosorbent assay [ELISA], Chemiluminescence Enzyme Immunoassays [CLIA], Fluorescence Immunoassays [FIA], and the Lateral Flow Immunoassays [LFIA]), targets (spike protein, receptor binding domain [RBD], and nucleocapsid), and antibody function (immunoglobulin [Ig] A, M, and G titer or neutralizing activity) measured by these tests also vary. Studies included in this systematic review utilized a combination of these humoral and/or cellular immunoassay in measuring the immune response against SARS-CoV-2 in HTX patients.

A prior history of COVID-19 prior to either dose of SARS-CoV-2 vaccine might have an impact on the robustness of the immune response among HTX recipients. In a case-control study of 26 heart/lung transplant recipients and 12 healthy controls, Lemieux et al. demonstrated a robust anti-RBD IgG response among the control group compared to a minimal response by heart/lung transplant recipients. However, those heart/lung transplant recipients with a history of COVID-19 prior to SARS-CoV-2 vaccination showed a comparable immune response to the healthy controls. While dysregulation of the immune system has been proposed as an underlying mechanism for a variable response to vaccination against COVID-19 in patients with a prior history of SARS-CoV-2 infection, time interval between the infection and vaccination seems to play a pivotal role in the strength of the immune response.
anti-thymocyte antibodies, calcineurin inhibitors (tacrolimus and cyclosporine), antimitobolites or antiproliferative agents (azathioprine, mycophenolate mofetil, and mycophenolate sodium), proliferation signal inhibitors or mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus), and glucocorticoids.39 There is a paucity of knowledge on the immunogenicity of SARS-CoV-2 vaccination in immunocompromised individuals including solid organ recipients (especially HTX patients) due to their exclusion from the flagship clinical trials.40-42 However, as elaborated in this systematic review, the immune response following any doses of SARS-CoV-2 vaccine has been sub-optimal among HTX recipients, especially in older patients within the first year of transplantation, and due to the use of an antimitobolite as an immunosuppressive agent. Whether a more aggressive approach is required and will be beneficial to immunize these vulnerable patients remains within the scope of future studies. Additionally, as more data is being published on the durability of immunity among patients with a prior dose of COVID-19 vaccine, a better understanding will be achieved for optimal scheduling of booster doses among HTX patients. Ideally, such information will arise from studies exclusively on immunocompromised patients so as to make the conclusion applicable to HTX recipients.

**Limitations**

Although this is the first systematic review summarizing available studies on the immune response to SARS-CoV-2 vaccine among HTX recipients, it harbors several limitations, mainly inherent to the current literature. A large body of the literature on immunization of HTX recipients comprises of case reports or case-control studies because SARS-CoV-2 clinical trials have excluded patients receiving cytotoxic or immunosuppressive regimens. Additionally, due to smaller sample size and retrospective methodology, the laws of cause and effect cannot be reliably investigated for a weaken immune response to the SARS-CoV-2 vaccine. This is especially true when the population of HTX recipients in either of these included studies are heterogeneous and of varying demographics, socioeconomic status, and clinical condition, which make the pooled analysis unfeasible. Finally, as the endpoint of most studies was quantification of antibody levels following immunization against SARS-CoV-2, they have fallen short at demonstrating the vaccine efficacy in the prevention of severe cases of COVID-19. Also, with evolving guidelines for booster vaccinations among immunocompromised patients, eyes will be on future studies to demonstrate the efficacy of additional doses of COVID-19 vaccine in eliciting a more robust immune response among HTX recipients. Such an endpoint needs to be compared to the general population in terms of infection rate by SARS-CoV-2, ICU admission, and mortality rate especially in the context of a deescalating pandemic.

**Conclusion**

This qualitative systematic review of the literature on the immune response to SARS-CoV-2 vaccine among HTX recipients observed that older age, being within the first year after the transplant, and use of antimitobolite as an immunosuppressive agent are implicated as potential factors associated with a weaken immune response. Cellular and humoral immunity seem to mount in parallel after vaccination against SARS-CoV-2, with a strong cellular response paving the way for a stronger humoral immunity.

**Acknowledgements**

We would like to extend our great appreciation to Ms. Lisa M. Parker for her extensive effort in reviewing this manuscript for language proficiency.

None of the authors received any financial support in any form.

**Author Contributions**

Saeed Shoar: Developing the idea; Study design; Data collection; Statistical analysis; Drafting the manuscript; and Critical revision of the final version.

Gabriel Patarroyo-Aponte: Data curation; Validation of the data; Writing – review and editing.

Ashok Chaudhary: Data curation; Investigation; Supervision; Validation; Writing – review & editing.

Mohammad Sadegh Asadi: Data curation; Investigation; Supervision; Writing – review & editing.

**ORCID iDs**

Saeed Shoar https://orcid.org/0000-0002-7000-0511

Gabriel Patarroyo-Aponte https://orcid.org/0000-0002-2676-6747

**REFERENCES**

1. Centers for Disease Control and Prevention. COVID Data Tracker. US Department of Health and Human Services, CDC. Accessed 03/20/2022, https://covid.cdc.gov/covid-data-tracker

2. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021[Internet]. Bethesda (MD): National Institutes of Health (US); 2021 Apr 21–2022 May 13. PMID: 34003615.

3. Kyriazopoulou E, Huet T, Cavalli G, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3(10):e690-e697. doi:10.1016/S2665-9913(21)00216-2

4. Kim M, Waanders NJB, Kosinta EJ, Gerretsen J, Pickkers P. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA Netw Open. 2020;3(4):1565-1567. doi:10.1001/jamanetworkopen.2020.17052

5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5

6. Shoar S, Hosseini F, Naderan M, Mehta JL. Meta-analysis of cardiovascular events and related biomarkers comparing survivors versus non-survivors in patients with COVID-19. Am J Cardiol. 2020;135:50-61. doi:10.1016/j.amjcard.2020.08.044

7. Diaz-Arocitua C, Cavallo-Castanedo D, Luis-Ybanez O, Pariona M, Rivas-Lasarte M, Alvarez-Garcia J. COVID-19 in heart transplant recipients during February-August 2020: a systematic review. Clin Transplant. 2021;35(9):e14390. doi:10.1111/ctr.14390
8. Iones OJ, Ballot K, Rao RS, Jones MA, Guglio M. SARS-CoV-2 infection in heart transplant recipients: a systematic literature review of clinical outcomes and immunomodulation strategies. *Heart Fail Rev*. 2021. [Epub ahead of print]. 1-11. doi:10.1007/s10741-021-10181-y

9. Vinton AJ, Dai R, Agarwal G, et al. Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19. *Am J Transplant*. 2022. Jan;22(1):245-259. doi:10.1111/ajt.18665

10. Akintoye E, Alvarez P, Shin D, et al. Changing demographics, temporal trends in waitlist, and posttransplant outcomes after heart transplantation in the United States: analysis of the UNOS database 1991–2019. *Circ Heart Fail*. 2021;14(11): e007674. doi:10.1161/CIRCHEARTFAILURE.121.007674

11. Ahmed F, Abid M, Maniya T, Usman MS, Fudim M. Incidence and prognosis of COVID-19 among heart transplant recipients: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2022. 29(6):e224-e226doi:10.1093/eurheart/jzwah175

12. Puleck FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N Engl J Med*. 2020;383(27):2603-2615. doi:10.1056/NEJMc2034577

13. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

14. Rosano G, Jankowska EA, Ray R, et al. COVID-19 vaccination in patients with heart failure: a position paper of the heart failure association of the European society of cardiology. *Eur J Heart Fail*. 2021;23(11):1806-1818. doi:10.1002/ejhf.2356

15. Nair V, Jayswal N, Hirsch JS, et al. An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. *Am J Transplant*. 2021;21(7):2522-2531. doi:10.1111/ajt.16460

16. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. *JAMA*. 2021;325(21):2204-2206. doi:10.1001/jama.2021.7489

17. Erbel-Khurtsidze S, Immohr MB, Akhyari P, et al. Adequate immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. *ESC Heart Fail*. 2021;8(7):1676-1678. doi:10.1002/ehf2.13635

18. Hallett AM, Greenberg RS, Boyarsky BJ, et al. SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients - a prospective cohort study. *Transplantation*. 2021;100:1345(21). doi:10.1097/tp.000000000000256. Epub ahead of print. 2021.09.006

19. Herrera S, Colmenero J, Pascal M, et al. Cellular and humoral immune response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. *Clin Res Cardiol*. 2021;110(8):1142-1149. doi:10.1007/s00392-021-01880-5

20. Tang WR, Hsu CW, Lee CC, et al. A case report of posttransplant lymphoproliferative disorder after AstraZeneca coronavirus disease 2019 vaccine in a heart transplant recipient. *Transplant Proc*. 2021. S0041-1345(21)00682-5. doi:10.1016/j.transproceed.2021.09.006

21. Mueller T. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological tests from the same manufacturer. *Clin Chem Lab Med*. 2021;59:18-19. doi:10.1515/cclm-2021-03077

22. Volka C, Covri-Souris C, Kuched D, De Mey C, Romisch J, Schmidt T. SARS-CoV-2 neutralization in convalescent plasma and commercial lots of plasma-derived immuno- globulin. *Biol Drugs*. 2021. 36(1):51-53. doi:10.1007/s40299-021-00511-9

23. Edwards KJ, Wilson A. COVID-19 vaccines. In: Hirsch MSB, Albyson, ed. UpToDate. UpToDate; 2022

24. EUA Authorized Serology Test Performance. Updated 12/03/2021. Accessed 12/26/2021. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices-eua-authorized-serology-test-performance

25. Bajema KL, Dahl RM, Etteren SL, et al. Comparative effectiveness and antibody responses to Moderna and Pfizer-BioNTech COVID-19 vaccines among hospitalized veterans - five veterans affairs medical centers, United States, February 1-September 30, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(49–50):1700-1705. doi:10.15585/mmwr.mm70492

26. Grange Z, Buodo A, Sullivan C, et al. Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland. *Lancet*. 2021;398(10313):1799-1800. doi:10.1016/S0140-6736(21)02316-3

27. Yek C, Warner S, Wiltrz JL, et al. Risk factors for severe COVID-19 outcomes among persons aged > = 18 years who completed a primary COVID-19 vaccination series - 465 health care facilities, United States, December 2020-October 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(11):19-25. doi:10.15585/mmwr.mm7101a4

28. Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm70383e1

29. Pham M. Heart transplantation in adults: induction and maintenance of immunosuppressive therapy. In: Dardas TF, ed. *UpToDate*. UpToDate; 2021

30. Walsh EE, French RV Jr, Falsy AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. *N Engl J Med*. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027996

31. Elia R, Reedy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. *Lancet*. 2021;398(10317):2173-2184. doi:10.1016/S0140-6736(21)00061-6

32. Kremers NG, Ahsad Guerrero RA, Arana-Ari E, et al. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. *Lancet Infect Dis*. 2022. 22(3):239-340. doi:10.1016/S1473-3099(21)00677-0